Arrowhead Pharmaceuticals' Insider Trading and Stock Performance

Company Overview - Arrowhead Pharmaceuticals (NASDAQ:ARWR) is a biopharmaceutical company focused on developing medicines that treat intractable diseases through RNA interference (RNAi) therapeutics [1] - The company competes with other biotech firms in the RNAi space, including Alnylam Pharmaceuticals and Ionis Pharmaceuticals [1] Insider Trading Activity - On January 5, 2026, Hamilton James C, the Chief Medical Officer, sold 4,625 shares at $61.24 each, retaining 207,497 shares post-sale [2] - Mauro Ferrari, a Director, sold 7,530 shares at an average price of $70, totaling $527,100, and reduced his ownership by 9.83% [3] - Ferrari previously sold 8,750 shares at $56.39 each, totaling $493,412.50 [3] Stock Performance - Arrowhead's stock opened at $66.39, reflecting a 1.3% decrease, and is currently priced at $63.88, down 5.77% or $3.91 [4] - The stock has fluctuated between $60.62 and $68 during the trading day, with a yearly high of $72.36 and a low of $9.57 [4] - The company's market cap is approximately $8.83 billion [4] Trading Volume and Momentum - The trading volume for ARWR today is 2,692,400 shares [5] - The stock's 50-day moving average is $53.54, indicating recent upward momentum despite recent insider sales [5][6] - Arrowhead remains a significant player in the biopharmaceutical industry, focusing on RNAi therapeutics [6]